Cinclus Pharma: partners with Zentiva in a deal worth EUR220m for its EU rights
Cinclus Pharma entered into a agreement with Zentiva for the EU rights of linaprazan glurate in a total deal value of EUR220m, including an upfront payment of EUR13m and a near-term milestone of EUR5m in 2026, and is entitled to receive tiered double-digit royalties on net sales in Europe, starting
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.